Lysine specific demethylase 1 inhibitor - Decoy Therapeutics
Alternative Names: LSD1i - Decoy TherapeuticsLatest Information Update: 28 Jan 2026
At a glance
- Originator Salarius Pharmaceuticals
- Developer Decoy Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for research development in Haematological-malignancies in USA
- 28 Jan 2026 No recent reports of development identified for research development in Solid-tumours in USA
- 13 Nov 2025 Salarius Pharmaceuticals has merged with Decoy Therapeutics to form Decoy Therapeutics